Navigation Links
Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
Date:4/27/2009

SAN DIEGO, April 27 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that Michael C. Scaife, Ph.D., has joined the organization as Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program.

"Michael brings to Orexigen over 26 years of solid experience in biotechnology and pharmaceutical product development, including 15 successful product approvals by the FDA," said Michael Narachi, the Company's President and Chief Executive Officer. "His appointment is timely as our foremost priority is to submit to the FDA the highest quality NDA and bring Contrave, our lead obesity product candidate, to market expeditiously."

In his role, Dr. Scaife will lead the development of Contrave (naltrexone sustained release (SR)/bupropion SR), which is on track for submission to the FDA in the first half of 2010. "I'm thrilled to join the Orexigen team, and I believe my development and regulatory experience will be invaluable as the Company works to help fill a significant unmet need in the fight against obesity," said Dr. Scaife.

Dr. Scaife has worked in leadership roles for a variety of device, drug and biopharma companies in both Europe and the United States. Prior to joining Orexigen, Dr. Scaife was Principal of MChS Consultancy Inc., a leading pharmaceutical development services agency. He also served as Senior Vice President of Global Regulatory Affairs, Pharmacovigilance and Drug Safety, Drug Information Services, Compliance and Quality Operations at Chiron Biopharma. In addition, Dr. Scaife held the position of Vice President of Quality and Regulatory Affairs for Nektar Therapeutics, Vice President of Global Regulatory Affairs for Elan Pharmaceuticals, and various regulatory an
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
2. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
3. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
4. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
5. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
6. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
7. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
8. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
9. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
10. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
11. United Therapeutics to Announce 2009 First Quarter Financial Results Before Market Open on Friday, May 1, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 BioHealth Innovation, Inc. ... biohealth innovations and increasing access to early-stage funding in ... venture capitalist, Tania Fernandez , Ph.D., has joined ... will be a member of the management team for ... to $50 million in seed and early-stage equity investments ...
(Date:9/30/2014)... CT (PRWEB) September 30, 2014 ... non-profit funder of Lyme disease research at universities, today ... researchers focused on the identification, treatment and cure for ... it had received the most applications in its history—over ... , “While we were pleased to receive so ...
(Date:9/30/2014)... New Jersey (PRWEB) September 30, 2014 ... it has been chosen by the Parenteral Drug ... (November 18 and 19, 2014) on container closure integrity ... container closure integrity test methods and philosophies detailed in ... – Integrity Evaluation. The course will span ...
(Date:9/29/2014)... Iraq and Afghanistan, more than 300,000 soldiers have returned ... by exposure to bomb blasts and in particular, ... traumatic brain injury can range from the mild, such ... in memory and cognition. , Since 2007, the ... and complexity of this problem, and has made significant ...
Breaking Biology Technology:Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 3Lyme Research Alliance Awards Nearly $600,000 in New Grants 4Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 3Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 4Modeling shockwaves through the brain 2Modeling shockwaves through the brain 3Modeling shockwaves through the brain 4
... skin tests at once with minimal patient discomfort, ... Unit announced today the launch of the ComforTen(TM) ... The device features ten,surgical steel 1.2mm lancet tips, ... ComforTen is the only 10-test, self-loading,surgical steel testing ...
... Nov. 9 Cadence Pharmaceuticals,Inc. (Nasdaq: CADX ... commercializing proprietary product candidates principally,for use in the ... its,third quarter ended September 30, 2007 financial results ... 2007. Cadence management will host a conference ...
... Dose and Data from First Randomized ... N.J., Nov. 8 Bristol-Myers Squibb,Company (NYSE: BMY ... (FDA) has approved new labeling for SPRYCEL to include ... and safety and,efficacy data in a greater number of ...
Cached Biology Technology:HollisterStier Offers Comfort With New ComforTen(TM) Multiple Skin Testing Device 2HollisterStier Offers Comfort With New ComforTen(TM) Multiple Skin Testing Device 3Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2007 Financial Results 2FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML 2FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML 3FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML 4FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML 5FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML 6FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML 7FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML 8FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML 9
(Date:9/30/2014)... The most comprehensive assessment conducted by the Ocean ... out of 100 in overall health. In addition, ... Antarctic and the 15 ocean regions beyond national ... maintaining a healthy climate, safeguarding biodiversity and providing ... update of the index, a partnership led by ...
(Date:9/30/2014)... 30, 2014--Sea monkeys have captured the popular attention of ... observable life cycle -- sold as dehydrated eggs, these ... little more than a tank of salt water. ... Like other zooplankton, brine shrimp vertically migrate in large ... to the surface at night and retreating deeper during ...
(Date:9/30/2014)... and Howard Hughes Medical Institute investigator, and Margarita ... in the 2014 round of grants from the ... (Brain Research through Advancing Innovative Neurotechnologies) Initiative for ... 30, provides more than $3 million in funding ... The BRAIN Initiative, launched last year, is a ...
Breaking Biology News(10 mins):Rating the planet's oceans 2Rating the planet's oceans 3Laser-guided sea monkeys show how zooplankton migrations may affect global ocean currents 2Salk scientists receive $3 million for BRAIN Initiative grant 2
... release is available in Spanish . , Agricultural ... wheat straw into ethanol "gold," and learning more about the ... production. At the ARS National Center for Agricultural ... conducted a 5-year study that examined whether wheat straw--a crop ...
... WASHINGTON, DC Fascinating advances across the spectrum ... be featured and explained through engaging table-top exhibits ... 16th Annual Exhibition and Reception. The exhibition/reception will ... Wednesday, April 14, in Rooms B338-340 of the ...
... old excuse, "I am only overweight because of my ... more evidence that the way our bodies digest and ... for every person. The budding discipline of metabolomics strives ... scientists and food chemists at the Technische Universitaet Muenchen ...
Cached Biology News:Cellulosic ethanol: Expanding options, identifying obstacles 2Science returns to Capitol Hill spotlight at April 14 exhibition 2Science returns to Capitol Hill spotlight at April 14 exhibition 3Science returns to Capitol Hill spotlight at April 14 exhibition 4Metabolic fingerprints offer fresh clues and a new path toward personalized medicine 2Metabolic fingerprints offer fresh clues and a new path toward personalized medicine 3
Mouse monoclonal [6G11] to Cytohesin 1 + 2 ( Abpromise for all tested applications)....
HNF-1 Purified Anti-Mouse, Anti-Rat, Anti-Rabbit, Anti-Human clone 2, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
Recombinant Porcine IL-1 alpha/IL-1F1, CF...
... siRNA Custom Synthesis Service provides ... RNA to knockdown any gene. ... RNA base pairs with terminal ... or other lengths of your ...
Biology Products: